🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

OCRA is pleased to announce Natera Oncology as the newest member of OCRA’s Gynecologic Cancer Collaborative. Learn more about the Collaborative’s work to advance cross-sector engagement & ensure patient-centric development of effective treatments: bit.ly/4kNin96. #GynCSM

Thank you to Colorectal Cancer Alliance for having Team Natera out at the annual #ScopeItOut event! We're always inspired by each survivor story and proud to discuss how our #MRD testing solutions helps support patients every step of the way. #CRCAwareness #CRCMonth #Natera

We are honored to witness the annual #UnitedinBlue flag installation BY Fight Colorectal Cancer. 🏛️💙 Their mission to empower CRC patients & drive change inspires us each year. Natera believes in the power of advocacy, and we support Fight CRC’s work! Learn more at ow.ly/suY150Vg3FU

🧬 Join us for a webinar and discussion surrounding the management of #CRC using #MRD testing and the role of #ctDNA in enabling new drug development opportunities in early-stage disease. Register today. ow.ly/PImg50VrHQ5 #Natera

📈 Nicole Scott, MS, PA-C presented key Signatera data and reviewed the clinical application of tumor-informed MRD testing to surgical oncologists at Society of Surgical Oncology entitled: "Tumor-informed ctDNA testing: transforming patient management in the perioperative setting". #Natera

We are proud to support patients with testing that can provide critical insights on their health. In this story from the Austin American-Statesman, you can learn more about our Signatera test for cancer recurrence. Christy, the patient featured in the story, describes the

Make more informed treatment decisions Learn how #Natera supports people on their healthcare journeys. #Oncology #CancerAwareness #Signatera

🔬 This Lab Week, we’re celebrating the dedicated teams from laboratory operations across Natera. Our lab teams are the heart of Natera, never losing sight that there’s a person behind each sample. Because of their work, we were able to serve more than 2 million patients last

Signatera Genome is now broadly available to U.S. physicians. Built from whole genome sequencing and powered by our patented mPCR-NGS technology, Signatera Genome delivers ultra-sensitive detection of circulating tumor DNA (ctDNA)—down to 1 part per million. Backed by a

In this clip from The Generalist podcast, Roelof Botha, partner at Sequoia Capital and board member at Natera, reflects on Natera and our co-founder Matthew Rabinowitz, including the personal story that led Matt to learn everything he could about biology and genetics and start the company. It

We recently announced the results of a study led by Stanford University School of Medicine on patients with soft tissue and bone sarcomas. With ~200 patients and >2,100 plasma samples across multiple distinct subtypes, this is the largest sarcoma cohort to date using

Dr. Karen Zaghiyan (Cedars-Sinai Academic Medicine) gave an informative presentation on using ctDNA in the perioperative setting at the American Society of Colon & Rectal surgeons annual meeting. #ASCRS #Natera ASCRS_1

🧬Dr. Jin K. Kim (Jin K Kim) presented the eposter: Using ctDNA to detect minimal residual disease in locally advanced rectal cancer post-TNT to #ASCRS2025 attendees. #Natera #CRC USF Health ASCRS_1

Be sure to attend our poster presentation "Analysis of Antibody-Drug Conjugate Usage in Patients Undergoing Circulating Tumor DNA Testing" on Thursday, May 15, 4:00 - 7:00 PM. #ISPORAnnual #CancerResearch

ASCO is one of the most important oncology meetings of the year, and together with our collaborators, Natera will share Signatera data from 25+ presentations across 10 different types of cancer. This includes: • Breast cancer: 8 accepted abstracts (4 oral presentations) •

Learn more about Signatera and the foundational technology that is transforming care for patients with cancer. Hear directly from Natera CEO Steve Chapman on how Signatera can detect molecular residual disease and help determine whether therapy is working. #CancerCare

👋Hello from ASCO 2025! Stop by our booth #13080 to learn more about our latest data. Be sure to catch our 30+ abstracts and oral presentations. 📊🧬 See below for details. ow.ly/rhxV50W1Osv #ASCO25 #Natera ASCO

Attending #ASCO25? Stop by booth #13080 to learn more about our expanding body of data in solid tumor malignancies and speak to our team!👋 📊🧬 ow.ly/3miK50W217z #ASCO25 #Natera ASCO

Every cancer survivor’s journey is a testament to strength—and a reminder of why our mission matters. We honor the lives touched by cancer and the progress still ahead. To every survivor, every family, and every clinician: you inspire our work every day. #NCSD2025 #Natera

What an incredible #ASCO25! We were thrilled to connect with everyone who came through our booth and want to thank the Naterans on our team for their hard work in making it a special event. Thank you to Marla Lipsyc-Sharf, MD, Julia Foldi, MD, PhD and Mridula George, MD